An Open, Non-Randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 Mg Monthly Dose of i.m. [intramuscular] Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

Trial Profile

An Open, Non-Randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 Mg Monthly Dose of i.m. [intramuscular] Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2012

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Planned end date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top